Name | Title | Contact Details |
---|---|---|
Jason Scharton |
Senior Director, Information Technology | Profile |
Mark Plavsic |
Chief Technical Officer | Profile |
Mark Plavsic |
Chief Technical Officer | Profile |
3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company`s lead candidate is a first-in-class, oral fatty acid synthase (FASN) inhibitor in Phase 1 clinical development that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V`s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.
Maxim Health Information Services is a Gardena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Comet Therapeutics addresses these profound unmet medical needs with its CoEnzyme Metabolism (CoMET™) Platform.
Oncology Care Associates is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.